small molecule

KRAZATI

ADAGRASIB

Loss of exclusivityAugust 2043latest FDA-listed patent expiry

CompanyBRISTOL MYERS SQUIBB CO

Drug detail

Brand name	KRAZATI
Active ingredient	ADAGRASIB
Strength	200MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	December 2022
Marketing status	RX

Listed patents

Patent	Expires	Type
12383503	August 2043	product
12281113	September 2041	substance, product
12336995	February 2041	use U-3953
10689377	May 2037	substance, product

Regulatory exclusivity

Code	Expires
ODE-352	December 2029
NCE	December 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from BRISTOL MYERS SQUIBB CO